Background:
Chronic Myeloid Leukaemia (CML) is the most prevalent blood malignancy in India. Anemia, splenomegaly, weight loss, fatigue are the most common symptoms and Imatinib, a first generation Tyrosine kinase inhibitor (TKI) is the choice of treatment.
Aim:
The objective of the study was to assess the etiology of anemia in CML and the pattern of pharmacotherapy, medication adherence and adverse drug reaction (ADR) in these patients in a tertiary care government hospital.
Methods:
This cross sectional observational study was conducted between January 2023 and May 2024 on 40 patients of all age groups and of both sexes, presented with CML and anemia to outpatient department of hematology. General, hematological and cytogenetic investigations were done to assess the outcome of treatment. Drug adherence and ADRs were also assessed.
Results:
Of the participants 25% were male and Imatinib mesylate, was the mainstay of treatment (92%) which is supplied free of cost. High rate of medication adherence was noted (85%). A total of 70 ADRs were noted among the patients participating in the study commonest being anemia (55%).
Conclusion:
Anemia remains a major problem in management of CML patients and need continuous assessment and management.
Key words: Chronic myeloid leukemia, Imatinib mesylate, Adverse drug reaction
|
